Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months

Anti‐platelet factor 4 immunoglobulin G levels in vaccine‐induced immune thrombocytopenia and thrombosis: Persistent positivity through 7 months

Abstract Background Anti‐platelet factor 4 (PF4) antibodies that activate platelets via FcγRIIA drive the pathophysiology of vaccine‐induced immune thrombocytopenia and thrombosis (VITT). Evolution of these antibodies and their ability to activate platelets after initial treatment remains unknown. O...

Full description

Bibliographic Details
Main Authors: Samantha J. Montague, Christopher W. Smith, Clare S. Lodwick, Charlotte Stoneley, Matthew Roberts, Gillian C. Lowe, William A. Lester, Steve P. Watson, Phillip L. R. Nicolson
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:Research and Practice in Thrombosis and Haemostasis
Subjects:
anti‐PF4 antibodies
AZD1222 vaccination
FcγRIIA
thrombosis
VITT
Online Access:https://doi.org/10.1002/rth2.12707

Internet

https://doi.org/10.1002/rth2.12707

Similar Items